SG52383A1 - Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions - Google Patents

Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions

Info

Publication number
SG52383A1
SG52383A1 SG1996003777A SG1996003777A SG52383A1 SG 52383 A1 SG52383 A1 SG 52383A1 SG 1996003777 A SG1996003777 A SG 1996003777A SG 1996003777 A SG1996003777 A SG 1996003777A SG 52383 A1 SG52383 A1 SG 52383A1
Authority
SG
Singapore
Prior art keywords
compositions
complement
producing
methods
carbohydrates
Prior art date
Application number
SG1996003777A
Other languages
English (en)
Inventor
Carol A Toht
Charles W Rittershaus
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of SG52383A1 publication Critical patent/SG52383A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG1996003777A 1993-05-17 1994-05-12 Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions SG52383A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6198293A 1993-05-17 1993-05-17

Publications (1)

Publication Number Publication Date
SG52383A1 true SG52383A1 (en) 1998-09-28

Family

ID=22039478

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996003777A SG52383A1 (en) 1993-05-17 1994-05-12 Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions

Country Status (11)

Country Link
US (1) US6193979B1 (de)
EP (1) EP0730608B1 (de)
JP (1) JP3662021B2 (de)
AT (1) ATE215094T1 (de)
CA (1) CA2162600C (de)
DE (1) DE69430253T2 (de)
DK (1) DK0730608T3 (de)
ES (1) ES2174876T3 (de)
PT (1) PT730608E (de)
SG (1) SG52383A1 (de)
WO (1) WO1994026786A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52383A1 (en) 1993-05-17 1998-09-28 T Cell Sciences Inc Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
EP0777474B1 (de) * 1994-09-23 2005-12-21 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von entzündlichen gelenkerkrankungen
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
WO2003097658A2 (en) 2002-05-16 2003-11-27 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
EP1539251A4 (de) * 2002-07-03 2009-02-25 Glycomimetics Inc Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
FR2861729B1 (fr) * 2003-10-31 2006-09-08 Fabre Pierre Dermo Cosmetique Monomere d'alkyl-rhamnose ou d'alkyl-fucose, medicament comprenant un monomere d'alkyl-sucre reducteur
US7361644B2 (en) * 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
JP2007524658A (ja) * 2003-11-19 2007-08-30 グリコミメティクス， インコーポレイテッド Ｅ−およびｐ−セレクチンの両方のための糖模倣物アンタゴニスト
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
EP2529746A1 (de) * 2005-06-06 2012-12-05 Girish J. Kotwal Vefahren zur Behandlung oder Prophylaxe von Reperfusionsschaden
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
EP1738763A1 (de) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Verwendung eines Komplement-inhibierenden Proteins zur Behandlung von Rückenmarksverletzungen
US7517980B2 (en) * 2005-08-09 2009-04-14 Glycomimetics, Inc. Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
PL1934236T3 (pl) 2005-09-02 2013-04-30 Glycomimetics Inc Heterobifunkcjonalne inhibitory pan-selektyny
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
US7964569B2 (en) 2006-10-12 2011-06-21 Glycomimetics, Inc. Glycomimetic replacements for hexoses and N-acetyl hexosamines
EP2083841B1 (de) * 2006-10-20 2013-11-20 Celldex Therapeutics, Inc. SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN ZUR BEHANDLUNG VON ALTERSBEDINGTEN MAKULADEGENERATION UND ANDEREN AUGENLEIDEN
EP2117561A1 (de) * 2007-02-09 2009-11-18 GlycoMimetics, Inc. Verfahren zur verwendung von glykomimetika mit substituten für hexosen und n-acetyl-hexosaminen
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009152245A1 (en) * 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
CN102421441B (zh) 2009-05-01 2015-04-01 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双功能抑制剂
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012037370A1 (en) * 2010-09-15 2012-03-22 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type i (scr1)
CA2815237C (en) 2010-10-27 2018-10-09 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
SI2794626T1 (en) 2011-12-22 2018-02-28 Glycomimetics, Inc. E-SELECTINE ANTAGONIST COMPOUNDS
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
JP7304863B2 (ja) 2017-12-29 2023-07-07 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンおよびガレクチン－３のヘテロ二機能性阻害剤
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US20210238238A1 (en) 2018-05-16 2021-08-05 Csl Limited Soluble complement receptor type i variants and uses thereof
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2021247487A1 (en) * 2020-06-01 2021-12-09 Medical University Of South Carolina Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4752569A (en) 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
IL82390A0 (en) 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
JPH05501359A (ja) 1990-04-27 1993-03-18 バイオジェン，インコーポレイテッド 付着分子発現に関与するフコシルトランスフェラーゼ
AU8007791A (en) 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
ES2183851T3 (es) 1990-07-17 2003-04-01 Univ Oklahoma Ligando de gmp-140.
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5164374A (en) 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
EP0512733A2 (de) 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
WO1992019735A1 (en) 1991-05-06 1992-11-12 Genentech, Inc. GLYCAM-1 (Sgp 50), A SELECTIN LIGAND
US5227369A (en) 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
SG52383A1 (en) 1993-05-17 1998-09-28 T Cell Sciences Inc Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions

Also Published As

Publication number Publication date
EP0730608A4 (de) 1998-12-02
US6193979B1 (en) 2001-02-27
EP0730608B1 (de) 2002-03-27
DE69430253T2 (de) 2002-11-14
DK0730608T3 (da) 2002-07-22
EP0730608A1 (de) 1996-09-11
CA2162600A1 (en) 1994-11-24
JP3662021B2 (ja) 2005-06-22
JPH08510257A (ja) 1996-10-29
PT730608E (pt) 2002-09-30
ES2174876T3 (es) 2002-11-16
DE69430253D1 (de) 2002-05-02
ATE215094T1 (de) 2002-04-15
AU678486B2 (en) 1997-05-29
WO1994026786A1 (en) 1994-11-24
AU6947594A (en) 1994-12-12
CA2162600C (en) 2000-07-11

Similar Documents

Publication Publication Date Title
SG52383A1 (en) Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
EP0295092A3 (en) Skin treatment composition
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
CA2015060A1 (en) Novel antibody delivery system for biological response modifiers
CA2223449A1 (en) Peptides and compounds that bind to the thrombopoietin receptor
EP0256714A3 (de) Kombinationstherapie mit Verwendung von Antitumor-Monoklonalen Antikörpern und/oder Immunotoxinen mit Interleukin-2
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
MX9702932A (es) L-ribofuranosilnucleosidos.
CA2090700A1 (en) Modified antibodies with controlled clearance time
ZA965686B (en) Cascade polymer complexes process for their production and pharmaceutical agents containing said complexes
BG104236A (en) Transgenous mammals producing oligosaccharides in their milk
SE9301951D0 (sv) Methods for administration of taxol
CA2040374A1 (en) Process for enhancing the resistance of aquatic animals to disease
MY113497A (en) Peptides and compounds that bind to a receptor
CA2253837A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
AU8970198A (en) N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in thetreatment of pain
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
CA2047721A1 (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
AU3255295A (en) Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
Gutterman Clinical investigation of interferons: status summary and prospects for the future